Lindenmann Joerg, Matzi Veronika, Neuboeck Nicole, Anegg Udo, Baumgartner Eva, Maier Alfred, Smolle Josef, Smolle-Juettner Freyja Maria
Division of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University Graz, Graz, Austria.
Lasers Surg Med. 2012 Mar;44(3):189-98. doi: 10.1002/lsm.22006. Epub 2012 Feb 14.
In esophageal carcinoma palliative treatment is often required due to advanced tumor stage or patient-related factors. The main goal of our retrospective single center study was to evaluate the effect of an individualized multimodal palliative treatment, focusing on the efficacy of different treatment options.
Between 1999 and 2009, 640 patients suffering from esophageal carcinoma were referred to our division. Two hundred fifty out of those (39.1%) were treated with palliative intention by using a individualized, multimodal concept including endoscopic dilatation, photodynamic therapy (PDT), endoluminal brachytherapy, external radiation, chemotherapy, stenting, feeding tube, and palliative resection.
There were 37 women (14.9%) and 211 men (85.1%). The treatment included PDT in 171 cases (in 118 as first measure), stenting in 124 (38), dilatation in 83 (24), endoluminal brachytherapy in 92 (20), feeding enterostomy in 40 (14), external radiation in 67 (23), chemotherapy in 57 (29), and palliative resection in 3 patients. The mean number of palliative treatments per patient was 2.6. Mean survival time for the collective was 34 months. Distant metastases and nodal positivity were connected with a significantly reduced survival. If PDT was used in the first place, median survival was 50.9 months compared to 17.3 months if other options were used as initial modality (P = 0.012).
By using an individualized multimodal approach, an acceptable mean survival time can be achieved in advanced esophageal cancer treated with palliative intention. PDT, if used as initial endoluminal treatment in patients without gross tumor infiltration into the mediastinum, the great vessels or the tracheo-bronchial tree, enables a considerable beneficial effect in the palliative setting.
在食管癌中,由于肿瘤分期较晚或与患者相关的因素,常常需要进行姑息治疗。我们这项回顾性单中心研究的主要目的是评估个体化多模式姑息治疗的效果,重点关注不同治疗方案的疗效。
1999年至2009年间,640例食管癌患者转诊至我科。其中250例(39.1%)采用个体化多模式理念进行姑息治疗,包括内镜扩张、光动力疗法(PDT)、腔内近距离放疗、外照射、化疗、支架置入、饲管置入及姑息性切除。
有37名女性(14.9%)和211名男性(85.1%)。治疗包括171例PDT(118例为首选措施)、124例支架置入(38例为首选措施)、83例扩张(24例为首选措施)、92例腔内近距离放疗(20例为首选措施)、40例饲管造口术(14例为首选措施)、67例外照射(23例为首选措施)、57例化疗(29例为首选措施)以及3例姑息性切除。每位患者姑息治疗的平均次数为2.6次。总体平均生存时间为34个月。远处转移和淋巴结阳性与生存率显著降低相关。若首先采用PDT,中位生存时间为50.9个月,而若首先采用其他方案,中位生存时间为17.3个月(P = 0.012)。
通过采用个体化多模式方法,对于接受姑息治疗的晚期食管癌患者可实现可接受的平均生存时间。在无肿瘤明显浸润纵隔、大血管或气管支气管树的患者中,若将PDT作为初始腔内治疗,在姑息治疗中可产生相当大的有益效果。